“
“The aim of this study was to determine the opinions of private medical practitioners in Bloemfontein, South Africa, regarding
euthanasia of terminally ill patients. This descriptive study was performed amongst a simple random sample of 100 of 230 private medical practitioners in Bloemfontein. Information was obtained through anonymous self-administered questionnaires. Written informed consent was obtained. learn more 68 of the doctors selected completed the questionnaire. Only three refused participation because they were opposed to euthanasia. Respondents were mainly male (74.2%), married (91.9%) and Afrikaans-speaking (91.9%). More were specialists (53.2%) than general practitioners (46.8%). A smaller percentage (35.5%) would never consider euthanasia for themselves compared to for their patients (46.8%). The decision should be made by the patient (50%), the patient’s doctor with two colleagues (46.8%), close family (45.2%) or a special committee of specialists in ethics and medicine (37.1%). The majority (46.9%) indicated that euthanasia should be performed LY2606368 clinical trial by an independent doctor trained in euthanasia, followed by the patient’s doctor (30.7%). Notification should mainly be given to a special committee (49.9%). Only 9.8% felt that no notification
was necessary. There was strong opposition to prescribing of medication to let the patient die. Withdrawal of essential medical treatment to speed up death was the most acceptable method. Although the responding group was fairly homogeneous, responses varied widely, indicating the complexity of opinions.”
“The aim of the present study was to evaluate check details the effectiveness of delmadinone acetate (DMA) for the treatment of hypersexuality (HS) and benign prostatic hypertrophy (BPH), which are frequently observed in male dogs, for which no surgical treatment has been indicated. The study was performed with 21 intact male dogs that had HS (n = 12) and signs of BPH (n = 9). DMA (Tardak(R) or Tardastrex(R)) was administered
subcutaneously to each dog at a dose of 3-5 mg/kg and was repeated 15 days later as a second treatment. DMA administration was repeated in some cases until the clinical signs disappeared. The successful recovery rate of HS cases was found to be 50% after a single application and 25% by the second and third applications. The mean “recovery periods” and mean “stable periods” of these 3 consecutive applications were found to be 5.83, 7.66, and 6.00 days, and 16.7, 18.7, and 20.0 months, respectively. With regard to BPH after consecutive applications, treatment success rates, mean recovery periods, and mean stable periods were 33.3%, 22.2%, 44.4%, 12.0, 11.0, 9.5 days, and >30, 12, and 13.5 months, respectively. DMA is clinically applicable as a therapeutic agent for HS and BPH cases; however, repeated applications were required due to temporary recoveries.